Study of the Anti-tumoral Immune Response T Cells Cluster of Differentiation 4 (TCD4): Proof of the Concept in Breast Cancer and Glioma
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 167
- 试验地点
- 1
- 主要终点
- Spontaneous immune responses of T cells CD4 specific tumor antigens
研究概览
简要总结
This study evaluates the frequency of the spontaneous T cells specific CD4 answers of tumoral antigens breast cancer and glioma.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Basic Science
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Performance status 0,1 or 2
- •breast cancer or glioma
- •Arm glioma: patients without anti-tumoral treatment
- •Arm breast cancer: inclusion before treatment
- •Arm breast cancer HER2: patients with current therapy
排除标准
- •Psychiatric disease compromising the understanding of the information or the realization of the study
- •vulnerable People according to the law (minors, adults under protection, private persons of freedom ...)
- •Unaffiliated People to the Social Security
- •People being for the period of exclusion from another study
- •Life expectancy estimated unless 3 months.
- •For patients in Arm glioma: patients having already begun a systematic treatment.
- •For patients with a breast cancer: patient already under current therapy
研究组 & 干预措施
glioma
1 additional blood sample for patients with glioma and without treatment
干预措施: additional blood sample (Other)
breast cancer
2 additional blood samples for patients with localized brest cancer, metastatic breast cancer in 1st line of treatment and breast cancer in second line of treatment.
干预措施: additional blood sample (Other)
breast cancer HER2+
1 additional blood sample for patients with metastatic breast cancer with HER2 surexpression
干预措施: additional blood sample (Other)
Breast Cancer HER 2+ or HER2 triple -
1 additional blood sample for patients with breast cancer HER2 + or HER2 triple negative treated by neo adjuvant
干预措施: additional blood sample (Other)
结局指标
主要结局
Spontaneous immune responses of T cells CD4 specific tumor antigens
时间窗: 15 months
次要结局
- T cells level(15 months)